Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (26742)	12/3/1998 2:48:00 PM
From: Mudcat	Read Replies (3) \| Respond to of 32384

Let me clear it up for you Bob. The Times reported that the FDA has been extremely lenient in approving drugs lately. Many of the approvers in a survey said that they have been approving drugs that really should not have been approved. My point is that even with the lenient approvals, Lgnd is having a hard time getting Panretin and Ontak approved. What would the delays be like if the FDA was actually following their own procedures (by the book)in approving Lgnd products. Also with the FDA being so lenient and still giving Lgnd a hard time is not a good indicator that their drugs and science are the "Slam Dunks" that Henry predicts. Hope this is simple enough for you to understand.